Obermatt
See Similar Stocks →

Fate Therapeutics

NMQ:FATE · US31189P1021
BiotechnologySmall

360

29
Profit price40
Cash yield1
Price/Sales48
Price/Book45
Return on Capital61
Cash Return on Capital37
Return on Equity43
Profit margins30
Accruals83
Owner Earnings Margin19
Sales growth44
Profit growth53
Reinvestment17
Price momentum42
Debt load15
Refinancing15
Debt Payback1
Liquidity74
Analyst ratings5
Opinion Changes86
Price Target Upside66
Market mood61
Value Creation2/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Fate Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Founded2007
Employees181
Websitefatetherapeutics.com
ISINUS31189P1021
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
ImmunologyStem Cell TherapyHematologyRheumatologyGeneticsOncologyBiotechnologyHealth CareTherapeutics

Description

Fate Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of off-the-shelf cellular immunotherapies to patients. The company has developed a therapeutic approach referred to as cel…

Analysis

Middle-of-the-road

Fate Therapeutics, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is adequate. The company scores 2/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
21
2026

All-time high

21

Jun 2026

All-time low

9

Mar 2026

Average rank

15

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
48
—
—
—
Price/Earnings
17
—
—
—
Price/Book
45
—
—
—
Dividend Yield
—
—
—
—
Value (overall)
37
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Fate Therapeutics with its peers
Sana Biotechnology
NSQ:SANA
63
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
BridgeBio Oncology Therapeutics
NMQ:BBOT
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Kyverna Therapeutics
NSQ:KYTX
6
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Nkarta
NSQ:NKTX
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Coeptis Therapeutics
NAQ:COEP
27
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Mink Therapeutics
NAQ:INKT
—
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →